The concurrent administration of FOLFOX aims at improving the likeliness of clinical responses in solid tumors by favoring infiltration into and overcoming the immunosuppressive tumor microenvironment (TME), improving engraftment of CAR-T cells due to the lymphodepletion induced by the chemotherapy, and likely increasing the NKG2D ligand expression in tumor tissues targeted by the NKG2D CARs (37). This evidence concerns the gene KLRK1 and neoplasm.